Startseite Effect of genetic subtypes and growth hormone treatment on bone mineral density in Prader-Willi syndrome
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Effect of genetic subtypes and growth hormone treatment on bone mineral density in Prader-Willi syndrome

  • Manaswitha Khare , June-Anne Gold , Marie Wencel , John Billimek , Abhilasha Surampalli , Bridgette Duarte , Andria Pontello , Pietro Galassetti , Suzanne Cassidy und Virginia E. Kimonis EMAIL logo
Veröffentlicht/Copyright: 7. Februar 2014
Journal of Pediatric Endocrinology and Metabolism
Aus der Zeitschrift Journal of Pediatric Endocrinology and Metabolism Band 27 Heft 5-6

Abstract

Background: Currently, there is limited information on the effects of growth hormone and of the different genetic subtypes on bone mineral density (BMD) in Prader-Willi syndrome (PWS).

Methods: We evaluated BMD in 79 individuals with the common subtypes of PWS (48 with deletion and 27 with UPD) and the effect of growth hormone treatment (n=46) vs. no growth hormone treatment.

Results: Forty-four percent of the individuals studied had whole body, hip, or spine BMD <–1 standard deviation (SD) and 10% had a BMD <–2 SD. BMD Z-scores and total BMD (g/cm2) of the spine were significantly higher in the growth hormone group. With each year of growth hormone treatment, these values increased by a factor of 0.207 and 0.011 (p=0.006 and 0.032), respectively. Individuals with uniparental disomy revealed higher spine BMD compared with deletion subclass; however, the differences were not significant.

Conclusion: This study emphasizes the importance of evaluating bone mineralization in individuals with PWS and the beneficial effects of prolonged treatment with growth hormone. There was a trend for a higher BMD in individuals with uniparental disomy.

Keywords: BMD; bone mineral density; osteopenia; osteoporosis; Prader-Willi syndrome; RDCRN (Rare Diseases Clinical Research Network); uniparental disomy
Corresponding author: Virginia E. Kimonis, MD, MRCP, Division of Genetics and Metabolism, Department of Pediatrics, University of California Irvine, 101 The City Drive South, ZC4482, Orange, CA 92868, USA, Phone: +1-714-456-5791, Fax: +1-714-456-5330, E-mail:

Acknowledgments

We thank the individuals and families who have contributed to this work and their health care providers. This study was supported by NIH U54 grants RR019478 and HD061222, Office of Rare Diseases Research. The authors acknowledge the other RDCRN sites involved in the Prader-Willi natural history study. We thank Drs. Daniel Driscoll, MD, Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, Merlin Butler, Departments of Psychiatry and Behavioral Sciences and Pediatrics, Kansas University Medical Center, Kansas City, KS, Elisabeth Dykens, Vanderbilt Kennedy Center, Vanderbilt University, Nashville, TN and their research groups for their encouragement and support for this study. We appreciate the gracious assistance of Dr. Mary Lou Oster-Granite, Health Scientist Administrator at NICHD, and Dr. Melissa Parisi, chief of the Intellectual and Developmental Disabilities Branch at the Eunice Kennedy Shriver, NICHD, NIH, who provided invaluable guidance, support, and encouragement for this rare disease initiative. The authors also thank the March of Dimes/Birth Defects Foundation for their grant (1999–2003) to study the earlier cohort, ICTS, UC Irvine, CA for funding, and the staff at the UC Irvine and Case Western Reserve for their invaluable help with this study.

References

1. Butler MG. Prader-Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet 1990;35:319–32.10.1002/ajmg.1320350306Suche in Google Scholar PubMed PubMed Central

2. Cassidy SB. Prader-Willi syndrome. J Med Genet 1997;34: 917–23.10.1136/jmg.34.11.917Suche in Google Scholar PubMed PubMed Central

3. Cassidy SB, Driscoll DJ. Prader-Willi syndrome. Eur J Hum Genet 2009;17:3–13.10.1038/ejhg.2008.165Suche in Google Scholar PubMed PubMed Central

4. Butler MG. Prader-Willi syndrome: obesity due to genomic imprinting. Curr Genomics 2011;12:204–15.10.2174/138920211795677877Suche in Google Scholar PubMed PubMed Central

5. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med 2012;14:10–26.10.1038/gim.0b013e31822bead0Suche in Google Scholar PubMed

6. Hauffa BP. One-year results of growth hormone treatment of short stature in Prader-Willi syndrome. Acta Paediatr Suppl 1997;423:63–5.10.1111/j.1651-2227.1997.tb18373.xSuche in Google Scholar PubMed

7. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002;87:1581–5.10.1210/jcem.87.4.8414Suche in Google Scholar PubMed

8. Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Troeman ZC, van Alfen-van der Velden AA, et al. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. J Clin Endocrinol Metab 2012;97:2307–14.10.1210/jc.2012-1182Suche in Google Scholar PubMed

9. Coupaye M, Lorenzini F, Lloret-Linares C, Molinas C, Pinto G, et al. Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood. J Clin Endocrinol Metab 2013;98:E328–35.10.1210/jc.2012-2881Suche in Google Scholar PubMed

10. Carrel AL, Allen DB. Prader-Willi syndrome: how does growth hormone affect body composition and physical function? J Pediatr Endocrinol Metab 2001;14:1445–51.10.1515/jpem-2001-0805Suche in Google Scholar PubMed

11. Johannsson G, Bengtsson BA. Growth hormone and the acquisition of bone mass. Horm Res 1997;48:72–7.10.1159/000191332Suche in Google Scholar

12. Bosio L, Beccaria L, Benzi F, Sanzari A, Chiumello G. Body composition during GH treatment in Prader-Labhardt-Willi syndrome. J Pediatr Endocrinol Metab 1999;12:351–3.Suche in Google Scholar

13. Craig ME, Cowell CT, Larsson P, Zipf WB, Reiter EO, et al. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol (Oxf) 2006;65:178–85.10.1111/j.1365-2265.2006.02570.xSuche in Google Scholar

14. Vestergaard P, Kristensen K, Bruun JM, Ostergaard JR, Heickendorff L, et al. Reduced bone mineral density and increased bone turnover in Prader-Willi syndrome compared with controls matched for sex and body mass index—a cross-sectional study. J Pediatr 2004;144:614–9.10.1016/j.jpeds.2004.01.056Suche in Google Scholar

15. Butler MG, Haber L, Mernaugh R, Carlson MG, Price R, et al. Decreased bone mineral density in Prader-Willi syndrome: comparison with obese subjects. Am J Med Genet 2001;103:216–22.10.1002/ajmg.1556Suche in Google Scholar

16. Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy X-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 1990;51:1106–12.10.1093/ajcn/51.6.1106Suche in Google Scholar

17. Galassetti P, Saetrum Opgaard O, Cassidy SB, Pontello A. Nutrient intake and body composition variables in Prader-Willi syndrome—effect of growth hormone supplementation and genetic subtype. J Pediatr Endocrinol Metab 2007;20:491–500.10.1515/JPEM.2007.20.4.491Suche in Google Scholar

18. Tothill P, Avenell A, Love J, Reid DM. Comparisons between Hologic, Lunar and Norland dual-energy X-ray absorptiometers and other techniques used for whole-body soft tissue measurements. Eur J Clin Nutr 1994;48:781–94.Suche in Google Scholar

19. Blake GM, Fogelman I. Interpretation of bone densitometry studies. Semin Nucl Med 1997;27:248–60.10.1016/S0001-2998(97)80027-XSuche in Google Scholar

20. Colmenares A, Pinto G, Taupin P, Giuseppe A, Odent T, et al. Effects on growth and metabolism of growth hormone treatment for 3 years in 36 children with Prader-Willi syndrome. Horm Res Paediatr 2011;75:123–30.10.1159/000319709Suche in Google Scholar PubMed

21. de Lind van Wijngaarden RF, Festen DA, Otten BJ, van Mil EG, Rotteveel J, et al. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial. J Clin Endocrinol Metab 2009;94:3763–71.10.1210/jc.2009-0270Suche in Google Scholar PubMed

22. Hoybye C. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment. Growth Horm IGF Res 2004;14:1–15.10.1016/j.ghir.2003.09.003Suche in Google Scholar PubMed

23. Myers SE, Carrel AL, Whitman BY, Allen DB. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr 2000; 137:42–9.10.1067/mpd.2000.105369Suche in Google Scholar PubMed

24. Lu PW, Briody JN, Ogle GD, Morley K, Humphries IR, et al. Bone mineral density of total body, spine, and femoral neck in children and young adults: a cross-sectional and longitudinal study. J Bone Miner Res 1994;9:1451–8.Suche in Google Scholar

25. Glastre C, Braillon P, David L, Cochat P, Meunier PJ, et al. Measurement of bone mineral content of the lumbar spine by dual energy X-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab 1990;70:1330–3.10.1210/jcem-70-5-1330Suche in Google Scholar PubMed

26. Hartley SL, Maclean WE, Jr., Butler MG, Zarcone J, Thompson T. Maladaptive behaviors and risk factors among the genetic subtypes of Prader-Willi syndrome. Am J Med Genet 2005;136:140–5.10.1002/ajmg.a.30771Suche in Google Scholar PubMed PubMed Central

27. Milner KM, Craig EE, Thompson RJ, Veltman MW, Thomas NS, et al. Prader-Willi syndrome: intellectual abilities and behavioural features by genetic subtype. J Child Psychol Psychiatry 2005;46:1089–96.10.1111/j.1469-7610.2005.01520.xSuche in Google Scholar PubMed

Received: 2013-5-11
Accepted: 2013-8-26
Published Online: 2014-2-7
Published in Print: 2014-5-1

©2014 by Walter de Gruyter Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Original articles
  3. Assessment of hearing in children with type 1 diabetes mellitus
  4. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy
  5. Increased hunger and speed of eating in obese children and adolescents
  6. Glucagon and insulin cord blood levels in very preterm, late preterm and full-term infants
  7. Thyroid function in late preterm infants in relation to mode of delivery and respiratory support
  8. Prevalence of vitamin D deficiency and its related factors in children and adolescents living in North Khorasan, Iran
  9. Asymmetric dimethyl L-arginine, nitric oxide and cardiovascular disease in adolescent type 1 diabetics
  10. A combined nutritional-behavioral-physical activity intervention for the treatment of childhood obesity – a 7-year summary
  11. The effect of earlier puberty on cardiometabolic risk factors in Afro-Caribbean children
  12. Prevalence of risk of deficiency and inadequacy of 25-hydroxyvitamin D in US children: NHANES 2003–2006
  13. Serum uric acid: relationships with biomarkers in adolescents and changes over 1 year
  14. Psychological impact on parents of children with congenital adrenal hyperplasia: a study from Sri Lanka
  15. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease
  16. Diseases accompanying congenital hypothyroidism
  17. Molecular diagnosis of a Chinese pedigree with α-mannosidosis and identification of a novel missense mutation
  18. Are the characteristics of thyroid cancer different in young patients?
  19. Unsaturated fatty acids and insulin resistance in childhood obesity
  20. Effect of genetic subtypes and growth hormone treatment on bone mineral density in Prader-Willi syndrome
  21. KCNJ11 gene mutation analysis on nine Chinese patients with type 1B diabetes diagnosed before 3 years of age
  22. Prevalence and risk factors of metabolic syndrome in school adolescents of northeast China
  23. Patient reports
  24. A novel activating ABCC8 mutation underlying neonatal diabetes mellitus in an infant presenting with cerebral sinovenous thrombosis
  25. Endocrinological anomalies in a patient with 12q14 microdeletion syndrome. Completing phenotype of this exceptional short stature condition
  26. Acute mental status change as the presenting feature of adrenal insufficiency in a patient with autoimmune polyglandular syndrome type II and stroke
  27. Effect of ethosuximide on cortisol metabolism in the treatment of congenital adrenal hyperplasia
  28. Absence of WNT4 gene mutation in a patient with MURCS association
  29. Identification of a novel insulin receptor gene heterozygous mutation in a patient with type A insulin resistance syndrome
  30. Adrenal insufficiency in association with congenital nephrotic syndrome: a case report
  31. Diabetic lipemia presenting as eruptive xanthomas in a child with autoimmune polyglandular syndrome type IIIa
  32. A case report of nephrogenic diabetes insipidus with idiopathic Fanconi syndrome in a child who presented with vitamin D resistant rickets
  33. Letter to the Editor
  34. Hyperbilirubinemia in neonates of diabetic mothers: an indirect biomarker of organ damage?
https://doi.org/10.1515/jpem-2013-0180
Schlagwörter für diesen Artikel
BMD; bone mineral density; osteopenia; osteoporosis; Prader-Willi syndrome; RDCRN (Rare Diseases Clinical Research Network); uniparental disomy

Artikel in diesem Heft

  1. Frontmatter
  2. Original articles
  3. Assessment of hearing in children with type 1 diabetes mellitus
  4. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy
  5. Increased hunger and speed of eating in obese children and adolescents
  6. Glucagon and insulin cord blood levels in very preterm, late preterm and full-term infants
  7. Thyroid function in late preterm infants in relation to mode of delivery and respiratory support
  8. Prevalence of vitamin D deficiency and its related factors in children and adolescents living in North Khorasan, Iran
  9. Asymmetric dimethyl L-arginine, nitric oxide and cardiovascular disease in adolescent type 1 diabetics
  10. A combined nutritional-behavioral-physical activity intervention for the treatment of childhood obesity – a 7-year summary
  11. The effect of earlier puberty on cardiometabolic risk factors in Afro-Caribbean children
  12. Prevalence of risk of deficiency and inadequacy of 25-hydroxyvitamin D in US children: NHANES 2003–2006
  13. Serum uric acid: relationships with biomarkers in adolescents and changes over 1 year
  14. Psychological impact on parents of children with congenital adrenal hyperplasia: a study from Sri Lanka
  15. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease
  16. Diseases accompanying congenital hypothyroidism
  17. Molecular diagnosis of a Chinese pedigree with α-mannosidosis and identification of a novel missense mutation
  18. Are the characteristics of thyroid cancer different in young patients?
  19. Unsaturated fatty acids and insulin resistance in childhood obesity
  20. Effect of genetic subtypes and growth hormone treatment on bone mineral density in Prader-Willi syndrome
  21. KCNJ11 gene mutation analysis on nine Chinese patients with type 1B diabetes diagnosed before 3 years of age
  22. Prevalence and risk factors of metabolic syndrome in school adolescents of northeast China
  23. Patient reports
  24. A novel activating ABCC8 mutation underlying neonatal diabetes mellitus in an infant presenting with cerebral sinovenous thrombosis
  25. Endocrinological anomalies in a patient with 12q14 microdeletion syndrome. Completing phenotype of this exceptional short stature condition
  26. Acute mental status change as the presenting feature of adrenal insufficiency in a patient with autoimmune polyglandular syndrome type II and stroke
  27. Effect of ethosuximide on cortisol metabolism in the treatment of congenital adrenal hyperplasia
  28. Absence of WNT4 gene mutation in a patient with MURCS association
  29. Identification of a novel insulin receptor gene heterozygous mutation in a patient with type A insulin resistance syndrome
  30. Adrenal insufficiency in association with congenital nephrotic syndrome: a case report
  31. Diabetic lipemia presenting as eruptive xanthomas in a child with autoimmune polyglandular syndrome type IIIa
  32. A case report of nephrogenic diabetes insipidus with idiopathic Fanconi syndrome in a child who presented with vitamin D resistant rickets
  33. Letter to the Editor
  34. Hyperbilirubinemia in neonates of diabetic mothers: an indirect biomarker of organ damage?
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 25.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpem-2013-0180/html
Button zum nach oben scrollen